Rethinking prescribing in the United States

British Medical Journal

Volumn 327, Issue 7428, 2003, Pages 1397-1400

  Ellner, Andrew ^a  

^a British Medical Journal Technology Assessment Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGING; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DEMOGRAPHY; DISABLED PERSON; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; GOVERNMENT; HEALTH CARE SYSTEM; HEALTH PROGRAM; LICENSING; ORGANIZATION; POLITICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; REIMBURSEMENT; REVIEW; TECHNIQUE; UNITED STATES;

EID: 0346848868     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7428.1397     Document Type: Review

References (19)

1. Kitchman M, Neuman T, Sandman D, Schoen C, Safran DG, Montgomery J, et al. Seniors and prescription drugs. Findings from a 2001 survey of seniors in eight states. Mento Park, CA: Henry J Kaiser Family Foundation, Commonwealth Fund, Tufts-New England Medical Center, 2002. www.kff.org/medicare/loader.cfm? url=/commonspot/security/ getfile.cfm&PageID=14177/ (accessed 1 Dec 2003).
2. Steinbrook R. The prescription drug problem. N Engl J Med 2002;346:790.
3. National Institute for Health Care Management Foundation. Prescription drugs and mass media advertising, 2000. www.nihcm.org/DTCbrief.pdf (accessed 16 Mar 2003).
4. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promodon of prescription drugs to consumers. N Engl J Med 2002;346:498-505.
5. Holmer AF. Direct to consumer advertising - strengthening our health system. N Engl J Med 2002;346:526-8.
6. Stuart B, Brandt N, Briesacher B, Fahlman C, Mullins D, Palumbo F, et al. Appendix A: issues on prescription drug coverage, pricing, utilization, and spending: what we know and what we need to know. In: Department of Health and Human Services. Report to the President: prescription drug coverage, spending, utilization and prices. Washington, DC, DHHS, 2000. http://aspe.hhs.gov/health/ reports/drugstudy/index.htm (accessed 10 Feb 2003).
7. Blumenthal D, Herdman R, eds. Description and analysis of the VA national formulary. Washington, DC: National Academy Press, 2000.
8. World Health Organization. The WHO model list of essential medicines. www.who.int/medicines/organization/par/edl/eml.shtml (accessed 1 Dec 2003).
9. World Health Organization. The selection of essential medicines. WHO Policy Perspect Med 2002;4. www.who.int/medicines/organization/ood/ ood6pagers.shtml (accessed 4 Nov 2003).
10. Goff VV. Pharmacy benefit managers: a model for Medicare? Issue Brief Natl Health Policy Forum 2001 Jul 9;(765):1-12.
11. American College of Physicians. Ambulatory care formularies and pharmacy benefit management by managed care organisations. Philadelphia, PA: ACP, American Society of Internal Medicine, 2001. www.acponline.org/hpp/ amb_care. htm (accessed 1 December 2003).
12. Horn S. HMO formularies and care costs. Lancet 1996;348:619-20.
13. Ross-Degnan D, Soumerai SB. HMO formularies and care costs. Lancet 1996;348:1264.
14. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000;283:2158-60.
15. Ionnides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002;20:577-91.
16. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumeria SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002;346:822-9.
17. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 2002;166:737-45.
18. Reference Drug Program Consultation Panel. Report to the minister of health planning, British Columbia, 2002. www.healthplanning.gov.bc.ca/ cpa/publications/rdppanel.pdf (accessed 4 November 2003).
19. Productivity Commission. International pharmaceutical price differences. Research report, July 2001. www.pc.gov.au/research/commres/ pbsprices/ finalreport/index.html.030530 (accessed 21 Apr 2003) .